Re-evaluating aspirin in the era of potent P2Y12 inhibitors: Ticagrelor monotherapy after percutaneous coronary intervention

Table 1 Characteristics of the studies included in the meta-analysis

Trial	Study design	Population/clinical setting	Sample size	DAPT run-in duration before randomization	Follow-up duration	Trial primary outcome	Outcomes used in this meta-analysis
TWILIGHT	Randomized, double-blind, placebo-controlled	High-risk patients undergoing PCI	7119	3 months	12 months	Clinically relevant bleeding (BARC 2-5) and ischemic composite (death, MI, stroke)	Clinically relevant bleeding (BARC 2/3/5), MACE (death, MI, stroke), NACE
TICO	Randomized, open-label with blinded endpoint adjudication	Acute coronary syndrome patients undergoing PCI (East Asian cohort)	3056	3 months	12 months	Composite of major bleeding and major adverse cardiac and cerebrovascular events	Major bleeding (TIMI major), ischemic outcomes, contributed to NACE
T-PASS	Randomized, open-label	Acute coronary syndrome patients undergoing PCI	As reported in trial publication	< 1 month	12 months	Composite of ischemic and bleeding events at 1 year	Major bleeding, MACE (approximated from reported event counts)
ULTIMATE-DAPT	Randomized, double-blind, placebo-controlled	Acute coronary syndrome patients undergoing PCI	As reported in trial publication	1 month	12 months	Clinically relevant bleeding with ischemic safety outcomes	Clinically relevant bleeding (BARC 2/3/5), major bleeding (BARC 3/5), MACE, NACE

PCI: Percutaneous coronary intervention; DAPT: Dual antiplatelet therapy; BARC: Bleeding Academic Research Consortium; MI: Myocardial infarction; MACE: Major adverse cardiac event; NACE: Net adverse clinical event; TIMI: Thrombolysis in myocardial infarction.